NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SYMBIOTEC · data 2026-10-31
Symbiotec Pharmalab Limited
In plain words
Price: 4.9% below its 52-week high of ₹1,309.9.
Delivery: 37.3% of traded shares were kept for delivery over the last 10 sessions, against 32.4% over the last 41.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | — |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 33.3%, pledged 38.5%, institutions 37.0%.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Promoters have pledged 38.5% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
39/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 32.2% over the last 20 sessions vs 28.1% in the 40 before (1.15x); shares delivered per day 0.3x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 11/20: Net +₹21.28 cr bought in bulk/block deals over 90 days (0.2x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 12/15: 0 insider buy days (promoter group among them) and 3 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 6 schemes hold it, about ₹422 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Deal
- 25 Sept 26Insider SAST disclosure: Beacon Trusteeship Limited acquired 47,48,208 shares +3.1% next session
- 24 Sept 26Insider SAST disclosure: Beacon Trusteeship Limited acting i… acquired 34,93,464 shares -5.5% next session
- 21 Sept 26Insider SAST disclosure: Mirae Asset Mutual Fund acquired 34,97,420 shares +2.4% next session
- 1 Sept 26Deal Bulk deal: TIMF HOLDINGS +1 bought ₹39.95 cr (net +₹21.28 cr)
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 |
|---|---|
| Promoters | 33.28% |
| Foreign institutions (FII) | 3.79% |
| Domestic institutions (DII) | 33.17% |
| Mutual funds | 12.18% |
| Retail investors | 6.70% |
| Number of shareholders | 81,747 |
Common questions
How much do promoters hold in Symbiotec Pharmalab Limited?
Promoters held 33.28% of Symbiotec Pharmalab Limited at the end of Sept 2026, with 38.54% of promoter shares pledged.
What is the 52-week high and low of Symbiotec Pharmalab Limited?
The 52-week high is ₹1,309.9 and the 52-week low is ₹934.2.
Mutual funds holding Symbiotec Pharmalab Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 6 schemes holding about ₹422 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Aggressive Hybrid Fund | Mirae Asset Mutual Fund | 0.99% | ₹92 cr |
| Mirae Asset Midcap Fund | Mirae Asset Mutual Fund | 0.45% | ₹88 cr |
| Mirae Asset Multicap Fund | Mirae Asset Mutual Fund | 1.20% | ₹65 cr |
| Mirae Asset ELSS Tax Saver Fund | Mirae Asset Mutual Fund | 0.26% | ₹64 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.00% | ₹58 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 1.60% | ₹56 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Symbiotec Pharmalab Limited | ₹1,246.3 | ₹8,001 cr | — | — | — | — | — | +26.1% |
| Aarti Pharmalabs Limited | ₹872.7 | ₹7,922 cr | 30.9 | 3.5 | 8.5% | 11.5% | 0.36 | +4.9% |
| Sanofi Consumer Healthcare India Limited | ₹3,442.3 | ₹7,911 cr | 28.3 | — | 73.1% | 82.8% | 0.06 | -26.8% |
| Sanofi India Limited | ₹3,204.1 | ₹7,380 cr | 20.2 | — | 40.6% | 54.6% | 0.02 | -33.2% |
| Suven Life Sciences Limited | ₹258.85 | ₹7,293 cr | — | — | -78.8% | -80.8% | 0.03 | +33.2% |
| Bliss GVS Pharma Limited | ₹647.5 | ₹6,894 cr | 51.4 | — | 11.5% | 10.9% | 0.02 | +325.8% |
Compare SYMBIOTEC with AARTIPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SYMBIOTEC in NSE Scanner →